Browse the evidence

Laparoscopic Roux-en-Y gastric bypass (LRYGB) results in higher rates of sustained excess weight loss compared to laparoscopic sleeve gastrectomy (LSG).

LRYGB may be a more effective option for patients seeking long-term weight loss.

A greater proportion of AOM-naïve patients achieved ≥15% and ≥20% total body weight loss at 12 months compared to non-AOM-naïve patients.

Clinicians should note that AOM-naïve patients are more likely to achieve significant weight loss with semaglutide.

Several agencies have approved tirzepatide for the treatment of type 2 diabetes and obesity.

Tirzepatide is a viable treatment option that is recognized by regulatory agencies for managing type 2 diabetes and obesity.

Brown adipose tissue (BAT) is identified as a thermogenic organ in human adults, which may be targeted for obesity and cardiometabolic disease treatment.

Activating BAT could be a novel strategy for treating obesity and related diseases.

Integrating shared decision-making (SDM) into obesity management enhances patient-centered care and has the potential to improve long-term outcomes.

Practitioners should consider incorporating SDM to enhance patient engagement and outcomes in obesity care.

Programs incorporating SDM reported improved patient engagement, satisfaction, and health outcomes across diverse demographic groups.

Incorporating SDM can lead to better patient experiences and outcomes in obesity management.

Common facilitators of SDM success include the use of decision aids, culturally tailored counseling, and multidisciplinary team involvement.

Healthcare providers should utilize decision aids and culturally tailored approaches to enhance SDM in obesity care.

Associations between obesity and health are likely causal.

Understanding that obesity has likely causal links to health can guide interventions.

Optimal selection of anti-obesity therapy requires consideration of patient factors and medication-related factors.

Healthcare providers should assess individual patient needs when prescribing anti-obesity medications.

The expanding array of anti-obesity medications provides valuable treatment options alongside lifestyle interventions and surgical approaches.

Integrating medications with lifestyle changes and surgical options can enhance obesity management.

Semaglutide is the most cost-effective treatment option in the severe obesity patient population and in first-tier cities in China.

In specific urban populations with severe obesity, semaglutide may be a preferred treatment option.

Lifestyle management was the most likely to be cost-effective under the willingness-to-pay threshold.

Lifestyle interventions should be prioritized for cost-effective obesity management.

Recent findings highlight promising signaling/targets for managing body weight, including appetite inhibition and energy expenditure.

Practitioners should focus on these signaling pathways for obesity interventions.

Weight loss in the GLP-1 RA group was directly associated with bone loss at the total hip (TH) and femoral neck (FN).

Weight management strategies may need to consider potential impacts on bone health.

The PMR diet was found to be safe, with no adverse events attributed to study participation.

The PMR diet can be safely implemented in clinical settings for stroke patients.

Participants in the PMR group reported barriers to weight loss, including food cravings and dislike for some food products.

Addressing food preferences and cravings may enhance adherence to PMR diets.

Roux-en-Y gastric bypass was associated with less gastroesophageal reflux disease (GERD)-related symptoms compared to sleeve gastrectomy.

Surgeons may prefer Roux-en-Y gastric bypass for patients concerned about GERD symptoms.

Physical activity contributes principally to the maintenance of weight loss rather than the induction of weight loss.

Emphasize physical activity for maintaining weight loss in treatment plans.

The study suggests that patient-delivered interventions may be effective in community and clinical settings for weight loss maintenance.

Consider exploring patient-delivered interventions in various settings for effective weight maintenance.

Male individuals lost a significantly larger proportion of weight as lean soft tissue (LST) compared to female individuals, with means of 0.33 kg and 0.25 kg respectively.

Practitioners should consider gender differences in body composition changes during weight loss interventions.

Quality of life outcomes generally showed improvements with incretin-based therapies (IBTs).

Clinicians can expect improvements in quality of life for patients using IBTs.

Fresh bread and rice consumption are associated with lower IBD risk.

Encouraging the consumption of fresh bread and rice may be beneficial for gut health.

Understanding patient concerns about the risks of obesity treatment is essential to addressing obesity treatment inertia.

Addressing these concerns may help improve treatment adherence and outcomes.

Baseline body fat percentage was significantly associated with weight gains (r = 0.57) and fat mass gains (r = 0.59) during an 8-week high-fat overfeeding intervention.

Practitioners should consider baseline body fat percentage when assessing weight gain responses to overfeeding.